This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Panzem

CASI Pharmaceuticals, Inc.

Drug Names(s): 2-methoxyestradiol, 2-ME2, 2ME2

Description: Panzem is Entremed's third anti-angiogenic agent in development. It is a natural estrogen metabolite with anti-angiogenic properties. It was discovered in Dr. Judah Folkman's lab by looking for natural products made by pregnant mothers during late stages of pregnancy.

Deal Structure: Allergan is working with EntreMed to develop Panzem for macular degeneration (AMD).

Panzem is currently bulk manufactured by Akzo Nobel.

EntreMed and CASI
In June 2014, EntreMed announced that at its annual meeting of stockholders, stockholders voted in favor of changing the companys corporate name to CASI Pharmaceuticals, Inc.

Actavis and Allergan
In November 2014, Actavis and Allergan announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share.

In March 2015, Actavis announced that it has completed the acquisition of Allergan in a cash and equity transaction valued at approximately $70.5 billion.

In June 2015, Actavis announced that the...See full deal structure in Biomedtracker

Partners: Allergan plc


Panzem News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug